Immunologic Research

, Volume 32, Issue 1, pp 155–168

CD25+CD4+ regulatory T-cells in cancer

Authors

    • Department of Surgery and Alvin J. Siteman Cancer CenterWashington University School of Medicine
  • Peter S. Goedegebuure
    • Department of Surgery and Alvin J. Siteman Cancer CenterWashington University School of Medicine
Article

DOI: 10.1385/IR:32:1-3:155

Cite this article as:
Linehan, D.C. & Goedegebuure, P.S. Immunol Res (2005) 32: 155. doi:10.1385/IR:32:1-3:155

Abstract

Regulatory T-cells (Treg) protect the host from autoimmune disease by suppressing self-reactive immune cells. As such, Treg may also block antitumor immune responses. Recent observations by us and others showed that the prevalence of Treg is increased in cancer patients, particularly in the tumor environment. Our studies in a mouse pancreas cancer model suggest that the tumor actively promotes the accural of Treg through several mechanisms involving activation of naturally occurring Treg as well as conversion of non-Treg into Treg. Our studies focus on further defining these mechanisms with the ultimate goal of designing strategies that block Treg-mediated suppression in cancer patients.

Key Words

Regulatory T-cellsSuppressionCancerAnticancer immunityDepletionTransforming growth factor-βFoxp3

Copyright information

© Humana Press Inc 2005